Phase I/II study of intermittent erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer.
Phase of Trial: Phase I/II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Docetaxel; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer.
- 02 Jun 2011 Planned end date changed from 1 Mar 2011 to 1 Mar 2013 University Hospital Medical Information Network - Japan.
- 22 Dec 2009 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.